Spyre Therapeutics (SYRE) Accounts Payables (2015 - 2026)
Spyre Therapeutics (SYRE) posted Accounts Payables of $5.7 million for Q1 2026, down 36.07% on a QoQ basis from $8.9 million in Q4 2025, and up 54.3% year-over-year from $3.7 million in Q1 2025.
Spyre Therapeutics (SYRE) Accounts Payables (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Accounts Payables history runs 12 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- Quarterly Accounts Payables rose 54.3% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 54.3% YoY) and the FY2025 annual result came in at $8.9 million, up 1236.94% from the prior year.
- Accounts Payables was $5.7 million for Q1 2026 at Spyre Therapeutics, down from $8.9 million in the prior quarter.
- Across five years, Accounts Payables topped out at $8.9 million in Q4 2025 and bottomed at $666000.0 in Q4 2024.
- A 5-year average of $3.6 million and a median of $3.2 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables sank 59.84% — and 2025, when it soared 1236.94%.
- Spyre Therapeutics' Accounts Payables stood at $4.2 million in 2022, then tumbled by 78.55% to $896000.0 in 2023, then decreased by 25.67% to $666000.0 in 2024, then surged by 1236.94% to $8.9 million in 2025, then tumbled by 36.07% to $5.7 million in 2026.
- Business Quant data shows SYRE's Accounts Payables at $5.7 million in Q1 2026, $8.9 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | 5.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.69 Mn |
| Dec 31, 2025 | 8.90 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Jun 30, 2025 | 3.71 Mn |
| Mar 31, 2025 | 3.69 Mn |
| Dec 31, 2024 | 666,000.00 |
| Sep 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 3.23 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 896,000.00 |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Mar 31, 2023 | 2.06 Mn |
| Sep 30, 2022 | 4.18 Mn |
| Jun 30, 2022 | 1.96 Mn |
| Mar 31, 2022 | 2.98 Mn |
| Dec 31, 2021 | 3.32 Mn |
| Sep 30, 2021 | 1.86 Mn |
| Jun 30, 2021 | 2.22 Mn |
| Mar 31, 2021 | 1.88 Mn |